Biotechnology industry veteran Kiran Mazumdar-Shaw has questioned Russian claims of developing the world's first safe coronavirus vaccine, citing absence of data on clinical trials and "more advanced" programmes elsewhere.
The world has not seen any data on Phase 1 or 2 clinical trials conducted by Moscow-based Gamaleya Research Institute, the Executive Chairperson of Bengaluru-headquartered Biocon Ltd said.
"If launching a vaccine prior to completion of Phase 3 trials is acceptable to Russia, well so be it," Mazumdar-Shaw told PTI.
ALSO READ: How rolling out Russia's Covid-19 vaccine without proper test can backfire
"But it doesn't make them the world's first vaccine as several other vaccine programmes are even more advanced," she added.
Russia announced on Tuesday it had become the first country to grant regulatory approval to a Covid-19 vaccine.
The first dose of the vaccine-Sputnik-V, developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry, was administered to Russian President Vladimir Putin's daughter.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)